Ignite Creation Date:
2026-03-26 @ 3:15 PM
Ignite Modification Date:
2026-03-30 @ 3:05 AM
Study NCT ID:
NCT07326592
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-03-06
First Post:
2026-01-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)
Sponsor:
CSL Behring
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2026-04-15
Start Date Type:
ESTIMATED
Primary Completion Date:
2033-09-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2033-09-15
Completion Date Type:
ESTIMATED
First Submit Date:
2026-01-07
First Submit QC Date:
None
Study First Post Date:
2026-01-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2026-03-05
Last Update Post Date:
2026-03-06
Last Update Post Date Type:
ACTUAL